Fate Therapeutics, Inc.

• Fate Therapeutics reports USD 2.08 million revenue for stock investors
  AD HOC NEWS · 20 Oct 2026
• Fate Therapeutics appoints Jamie Harrell to lead commercial strategy By Investing.com
  Investing.com South Africa · 12 Oct 2026
• Fate Therapeutics appoints Jamie Harrell to lead commercialization
  Investing.com · 12 Oct 2026
• Fate Therapeutics names Jamie Harrell SVP of commercial operations
  StreetInsider · 12 Oct 2026
• Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics.
  Stock Titan · 12 Oct 2026
• Fate Therapeutics Appoints Jamie Harrell as Senior Vice
  GlobeNewswire · 12 Oct 2026
• Fate Therapeutics appoints Jamie Harrell to lea...
  Pluang · 12 Oct 2026
• Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating
  Moomoo · 05 Oct 2026
• CIRM Awards Fate Therapeutics $15M for FT819 Lupus Nephritis Trial
  The Clinical Trial Vanguard · 29 Sep 2026
• Fate Therapeutics lands $15M CIRM grant for lupus cell therapy trial
  Dealroom · 29 Sep 2026
• Is Fate Therapeutics (NASDAQ:FATE) Rewriting the Healthcare Stocks Playbook?
  Kalkine Media · 28 Sep 2026
• Fate Therapeutics Announces Receipt of California Institute
  GlobeNewswire · 25 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →